CLESITAMIG
UNII H57D6SR4FE
Substance Identification & Data
This profile provides standardized clinical and technical data for Clesitamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) H57D6SR4FE.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2930861-48-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
H57D6SR4FE
2930861-48-4
N/A
Detailed Substance Profile
Preferred Name
CLESITAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13237
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Clesitamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Clesitamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Clesitamig
Common Names & Synonyms
Immunoglobulin, anti-(human notch ligand DLL3 extracellular domain) (human-Oryctolagus cuniculus monoclonal D08410053H0118/D084101L0000 light chain variable region) fusion protein with peptide linker (SS) fusion protein with immunoglobulin (human γ1-chain CH1 region) fusion protein with peptide linker (EPKSCGGGGS) fusion protein with immunoglobulin G1 [158-glutamic acid,202-cysteine,224-glutamic acid,245-alanine,246-alanine,308-alanine,365-cysteine,377-tryptophan,439-leucine,445-alanine,449-arginine,451-glutamic acid,de-457-glycine,de-C-terminal-lysine] anti-(human CD3 antigen/tumor necrosis factor receptor TNFRSF9) (human monoclonal dBBDu183H1643/dBBDu072L0581 γ1-chain), (Cys-422→Cys-202′),(Cys-457→Cys-237′),(Cys-460→Cys-240′),(Cys-585→Cys-360′)-tetra(disulfide) with immunoglobulin G1 [158-glytamic acid,202-cysteine,224-glutamic acid,245-alanine,246-alanine,308-alanine,360-cysteine,377-serine,379-alanine,418-valine,439-leucine,445-alanine,449-arginine,451-glutamic acid,de-457-glycine,de-C-terminal-lysine] anti-(human CD3 antigen/tumor necrosis factor receptor TNFRSF9) (human monoclonal dBBDu183H1643/dBBDu072L0581 γ1-chain), (Cys-215→Cys-226")-disulfide with immunoglobulin anti-(human notch ligand DLL3 extracellular domain) (human-Oryctolagus cuniculus monoclonal D08410053H0118/D084101L0000 heavy chain variable region) fusion protein with immunoglobulin [1-alanine,2-serine] (human κ-chain constant region), (Cys-451→Cys-219′′′)-disulfide with immunoglobulin [128-arginine,129-lysine] anti-(human CD3 antigen/tumor necrosis factor receptor TNFRSF9) (human monoclonal dBBDu183H1643/dBBDu072L0581 κ-chain), (Cys-231′→Cys-219′′′′)-disulfide with immunoglobulin [128-arginine,129-lysine] anti-(human CD3 antigen/tumor necrosis factor receptor TNFRSF9) (human monoclonal dBBDu183H1643/dBBDu072L0581 κ-chain)
clesitamig [INN]
fused heavy chain V-kappa-G4CH1-G1h anti-DLL3-H-gamma1 anti-CD3/TNFRSF9 (1-676) [V-kappa-G4CH1-G1h anti-DLL3 humanized (1-215) [V-KAPPA (Homo sapiens IGKV1-33*01 (76.3%) -IGKJ4*01 (100%), CDR-IMGT [8.3.10] (27-34.52-54.91-100)) (1-110) -2-mer diseryl (111-112)- Homo sapiens IGHG4*01 G4v97 S10 (CH1 C10>S (126) (113-210) -IGHG1*01 hinge 1-5 (211-215)) (113-215)] -5-mer (tetraglycyl-seryl) linker (216-220) -H-gamma1 heavy chain humanized, anti-CD3/TNFRSF9 (221-676) [VH (Homo sapiens IGHV3-72*01 (78.6%) -(IGHD) -IGHJ6*01 (86.7%), CDRIMGT [8.10.19] (246-253.271-280.319-337)) (221-348) -Homo sapiens IGHG1*01 G1m17,1 CH1 K120, CH3 D12, L14, G1v57 CH1 E26, E119, G1v94 CH1 C94, G1v14 CH2 A1.3, A1.2, G1v29 CH2 A84.4, G1v74 CH3 C10, G1v32 CH3 W22 (knob), G1v78 CH3 L107, A114, G1v89 CH3 R118, E120 (CH1 K26>E (378), S94>C (422), K119>E (444), K120 (445) (349-446), hinge 1-15 (447-461), CH2 L1.3>A (465), L1.2>A (466), N84.4>A (528) (462-571), CH3 S10>C (585), D12 (587), L14 (589), T22>W (597), M107>L (659), N114>A (665), Q118>R (669), S120>E (671) (572-676)) (349-676)]]; (215-226')-disulfide with the VH-C-kappa light chain anti-DLL3 humanized (1'-226') [VH (Homo sapiens IGHV4-61*02 (72.0%) -IGHD -IGHJ4*01 (86.7%), CDR-IMGT [9.8.11] (26'-34'.52'-59'.98'-108')) (1'-119') -Homo sapiens IGKC*01 (99.1%) Km3 A45.1, V101, KCv96 A1.4, S1.3 (C-KAPPA R1.4>A (120'), T1.3>S (121'), A45.1 (165'), V101 (203')) (120'-226')]; (451-219''')-disulfide with common L-kappa light chain humanized, anti-CD3/TNFRSF9 (1'''-219''') [V-KAPPA (Homo sapiens IGKV2-30*02 (80.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27'''-37'''.55'''-57'''.94'''-102''')) (1'''-112''') -Homo sapiens IGKC*01 (98.1%) Km3 A45.1, V101, KCv57 R12, K13 (C-KAPPA E12>R (128'''), Q13>K (129'''), A45.1 (158'''), V101 (196''')) (113'''-219''')]; H-gamma1 heavy chain anti-CD3/TNFRSF9 humanized (1''-456'') [VH (Homo sapiens IGHV3-72*01 (78.6%) -(IGHD) -IGHJ6*01 (86.7%), CDR-IMGT [8.10.19] (26''-33''.51''-60''.99''-117'')) (1''-128'') -Homo sapiens IGHG1*01 G1m17,1 CH1 K120, CH3 D12, L14, G1v57 CH1 E26, E119, G1v94 CH1 C94, G1v14 CH2 A1.3, A1.2, G1v29 CH2 A84.4, G1v75 CH3 C5, G1v33 CH3 S22, A24, V86 (hole), G1v78 CH3 L107, A114, G1v89 R118, E120 (CH1 K26>E (158''), S94>C (202''), K119>E (224''), K120 (225'') (129''-226''), hinge 1-15 (227''-241''), CH2 L1.3>A (245''), L1.2>A (246''), N84.4>A (308'') (242''-351''), CH3 Y5>C (360''), D12 (367''), L14 (369''), T22>S (377''), L24>A (379''), Y86>V (418''), M107>L (439''), N114>A (445''), Q118>R (449''), S120>E (451'') (352''-456'')) (129''-456'')], (231''-219'''')-disulfide with common L-kappa light chain humanized, anti-CD3/TNFRSF9 (1''''-219'''') [V-KAPPA (Homo sapiens IGKV2-30*02 (80.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27''''-37''''.55'''-57''''.94''''-102'''')) (1''''-112'''') -Homo sapiens IGKC*01 (98.1%) Km3 A45.1, V101, KCv57 R12, K13 (C-KAPPA E12>R (128''''), Q13>K (129''''), A45.1 (158''''), V101 (196'''')) (113''''-219'''')]; heterodimer (422-202'':457-237'':460-2
immunoglobulin [(V-kappa-G4CH1-G1h-H-gamma1_L-kappa)_Lkappa)]_(H-gamma1_L-kappa), anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], anti-[Homo sapiens CD3/TNFRSF9 (TNF receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137) dual non simultaneous], humanized monoclonal antibody, trispecific, trivalent
